Objective. To test the hypothesis that patients with limited cutaneous systemic sclerosis (SSc) have a higher incidence of lower limb large vessel disease than patients with diffuse cutaneous disease, and that anticentromere antibody is a risk factor for lower limb large vessel disease.
Systemic sclerosis (SSc) is a multisystem connective tissue disease characterized by vascular abnormalities, fibrosis, and activation of the immune system. There are two major disease subtypes, defined according to the extent of skin involvement: limited cutaneous (LCSSc) and diffuse cutaneous SSc (DCSSc) w1x. The two subtypes have different clinical courses, serology and prognosis. Patients with diffuse disease tend to have rapid skin and internal organ involvement early in their disease course, while patients with limited disease tend to have Raynaud's phenomenon for many years preceding other clinical manifestations of their disease. As a generalization, fibrosis (for example of the skin and lungs) is more pronounced in DCSSc than in LCSSc, whereas vascular abnormalities are more pronounced in patients with LCSSc who often develop severe Raynaud's phenomenon, telangiectases, and 'primary type' pulmonary hypertension in later disease. How the vascular abnormalities and fibrosis interrelate is not understood, but it has been suggested that SSc is primarily a vascular disease w2x. Traditionally it has been thought that it is the microvasculature which is primarily affected, as well demonstrated using the technique of nailfold microscopy w3x. However, in recent years increased attention has focused on the possibility that large vessel involvement also occurs and is a major contributor to the morbidity of the disease w4-6x.
Anticentromere antibody is known to be a risk factor for severe digital ischaemia w7, 8x, and occurs mainly in patients with limited cutaneous disease. We have recently shown, using nailfold capillaroscopy w9x and laser Doppler imaging w10x that patients with LCSSc have more severe digital microvascular disease than those with DCSSc. In recent years, checking of the ankle brachial pressure index (ABPI) has formed part of our routine assessment of patients with SSc, and with the recent interest in large vessel disease in SSc we undertook a retrospective study to test the hypothesis that patients with LCSSc have a higher incidence of lower limb large vessel disease than patients with DCSSc, and that anticentromere antibody is a risk factor for lower limb large vessel disease.
Methods

Patients
This was a retrospective review of clinical and laboratory data of 119 patients from the SSc clinic in Hope Hospital, Salford, who had had their ABPI checked between March 1997 and January 2000. The age, sex, drug treatment, smoking history, disease subtype, and anticentromere antibody status were documented. ABPI of both right and left lower limbs were measured. When ABPI had been checked more than once within the time frame of the study, the first value was considered. Any history of ischaemic stroke, intermittent claudication, and ischaemic heart disease was identified from the case notes.
Non-invasive vascular assessment
Peripheral circulation was assessed using a Hokanson CW 1 Doppler ultrasound machine with a 5 MHz probe. After a 5-min period of rest, the brachial artery pressure was measured in the supine position. The dorsalis pedis and posterior tibial pressures were then measured and ABPI calculated, using the highest value, by dividing ankle pressure by the brachial artery pressure. The normal value of ABPI is 1.0. Any value below 1.0 is abnormal and inversely proportional to the severity of peripheral vascular disease w11x.
Statistical analysis
The lower ABPI in the left and right legs for each patient was used (two patients only had one measurement due to unilateral below knee amputation). Analysis of variance was used to compare groups, with adjustment for smoking where stated. ABPI values showed some non-normality due to a few particularly low values. However, when the effect of these extreme values was examined in a sensitivity analysis, the results were very robust.
Results
The demographic data of the 119 patients studied are given in Table 1 . Seventy-one of these patients (50 of the 91 with limited and 21 of the 28 with diffuse cutaneous disease) were on vasodilator therapy. Five of the patients had intermittent claudication. All had limited cutaneous disease and four were anticentromere antibody positive, and one had had an ischaemic stroke (this patient was anticentromere negative). In addition, two of these five patients had had unilateral below knee amputations. Four patients had ischaemic heart disease-two with limited cutaneous disease (one anticentromere antibody positive) and two with diffuse cutaneous disease (one anticentromere antibody positive). Three patients had had an ischaemic stroketwo with limited cutaneous disease (one anticentromere antibody positive) and one with diffuse cutaneous disease.
Fourteen (12%) patients (11 patients with LCSSc and three patients with DCSSc) had an ABPI of less than 1.0 (either right or left lower limb).
Age and smoking
There was no association between age and ABPI (r s = 20.04, P = 0.65). The median ABPI in smokers was 1.05 (range 0.36-1.33) and in non-smokers was 1.12 (range 0.75-1.38). Smoking was associated with a reduced ABPI (P = 0.001). The average reduction was 0.11 w95% confidence interval (CI) 0.05-0.17x. (Fig. 1a) The median ABPI in patients with LCSSc was 1.1 (range 0.36-1.38) and in patients with DCSSc it was 1.1 (range 0.86-1.29). The analysis of LCSSc vs DCSSc was adjusted for the effect of smoking. There was no evidence of reduced ABPI in LCSSc (P = 0.65), average reduction 0.01 (95% CI 20.04 to +0.07).
LCSSc vs DCSSc
Effect of anticentromere antibody (Fig. 1b) The median ABPI in patients who were anticentromere antibody positive was 1.07 (0.36-1.38) compared with 1.11 (0.66-1.36) in those who were anticentromere antibody negative. After adjusting for the effect of smoking, there was some suggestion of reduced ABPI in anticentromere antibody-positive patients (P = 0.12), average reduction 0.04 (95% CI 20.01 to +0.09).
Discussion
Our study suggests that ABPI is not reduced in patients with LCSSc when compared with those with DCSSc. These findings therefore refute our original hypothesis that patients with limited cutaneous disease are at higher risk of lower limb large vessel disease than those with diffuse cutaneous disease.
From the findings of the present study we conclude that anticentromere antibody may be weakly associated with severity of large vessel disease, although differences in ABPI between patients who were anticentromere antibody positive and negative were not statistically significant. Anticentromere antibody positivity has been previously linked with severity of vascular disease w7, 8, 12x and interestingly not all of the six anticentromere-positive patients reported by Takahashi et al. w12x had definite SSc. However, from our previous work we believe that the higher prevalence of digital vascular problems in patients with limited cutaneous disease may relate largely to their more severe microvascular disease w9, 10x.
Although the numbers with symptomatic large vessel disease were small, it is worth noting that four of the five patients with intermittent claudication, two of the four patients with ischaemic heart disease, and one of the three patients with ischaemic stroke were anticentromere antibody positive, as compared with 38% of our overall cohort of 119 patients. Therefore, anticentromere antibody was over-represented in the symptomatic group, at least in those with intermittent claudication or ischaemic heart disease. Also, both the patients who had had below knee amputations were anticentromere antibody positive. As anticipated, patients who smoked had lower ABPI than those who did not, but analyses of disease subtype and anticentromere antibody status were adjusted for smoking.
Previous studies which have systematically examined the macrovasculature of patients with SSc did not set out to compare patients on the basis of their disease subtype w4, 5x. Youssef et al. w6x only studied patients with LCSSc. Our study suggests that disease subtype does not have a major influence on lower limb macrovascular disease. Our study was a retrospective study, and we are very aware that we did not have information on other risk factors for large vessel disease such as blood glucose and cholesterol. However, we have no reason to believe that blood glucose or cholesterol would be likely to differ between patients with limited or diffuse cutaneous disease.
Our study was purely a comparison of LCSSc and DCSSc, and it was not our purpose to make comparisons with a control population. While our prevalence of lower limb large vessel disease (12% of patients had an ABPI of less than 1.0) might appear low in comparison with other studies w4-6x, it is not possible to draw conclusions about this without conducting a much more comprehensive study including a control population from northwest England, and this was outwith the scope of the current study. Similarly, it is not possible to compare the incidence of symptomatic macrovascular disease between studies because in our study this was identified purely by case note review, whereas Veale et al. w4x administered a claudication questionnaire in addition to reviewing the case notes. It is likely that in our population the prevalence of symptomatic large vessel disease has been underestimated.
Whether lower limb large vessel disease in SSc is atherosclerotic is currently an open question w5x. However, the possibility of less usual causes, such as vasculitis w13x or an antiphospholipid syndrome w14x, should always be considered. Fortunately the necessity for lower limb amputation occurs rarely in patients with SSc w15x and only two of our patients had had below knee amputations.
In conclusion, the prevalence of lower limb macrovascular disease is likely to be similar in both subtypes of SSc. There may be a weak association with anticentromere antibody. The key point for the clinician is that digital ischaemia and ulceration in the patient with SSc may be due to large vessel as well as to small vessel disease and optimal management of the patient needs to take this into account. 
